Business Wire

SES

28.4.2021 08:52:11 CEST | Business Wire | Press release

Share
SES’s Next-Gen NGSO System Readies for Launch with 8 Initial O3b mPOWER Satellite Ground Stations

SES announced today that it has signed agreements with key infrastructure service providers around the world to build its eight initial O3b mPOWER satellite ground stations. Construction has already started on these advanced technology satellite ground stations, which will become operational in the second half of this year. The eight sites will provide telemetry, tracking and control capabilities to enable SES’s management of the constellation. They will also be leveraged to raise the satellites into the right orbit after the scheduled launches.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427006193/en/

As previously announced, two of the satellite ground stations are located at Dubbo, NSW, Australia (operated by Pivotel) and Thermopylae, Greece (operated by OTE) . Other locations include Merredin, Perth, Australia; Phoenix, Arizona, US; Chile; the United Arab Emirates; Senegal as well as SES’s own satellite ground station in Hawaii. Four out of the eight sites will be co-located and operated with Microsoft’s Azure data centres ; the one-hop connectivity to the cloud from remote sites will provide O3b mPOWER customers the ability to optimise business operations with significant flexibility and agility.

O3b mPOWER is SES’s next-generation Medium Earth Orbit (MEO) system. Building on the success of O3b, each of the 11 high-throughput, low-latency O3b mPOWER satellites will deliver high-speed connectivity services from tens of megabits to multiple gigabits per second, providing fibre-like connectivity to customers globally.

The O3b mPOWER satellite ground stations have many technically advanced features compared to the existing O3b satellite ground station. They include a new generation of fast-install 5.5-metre carbon fibre antennas which can be installed without the need for expensive and time-consuming photogrammetry. In addition, they will utilise energy-efficient solid-state power amplifiers, and a low electrical load for the antenna control unit (ACU).

The satellite ground stations will use SES’s gateway management system for automated operations and handovers, which will be tightly integrated with SES’s unique resource management capability, Adaptive Resource Control (ARC) and other SES software sub-systems. With this configuration, SES will dynamically manage and optimise space and ground resources to meet the changing needs of its customers. These combined technology advances result in improved efficiency and lower total cost of ownership.

The first three O3b mPOWER satellites are scheduled for launch in the third quarter of this year, with the next three in the first quarter of 2022. After orbit raising, O3b mPOWER will start delivering services in the third quarter of 2022.

Stewart Sanders, Executive Vice President of Technology and O3b mPOWER programme manager at SES, said, “We are thrilled to have chosen these eight locations and construction is underway. We are also deep in discussions with several telco players and operators who are keen to have their own O3b mPOWER satellite ground station. This is particularly exciting, as it means that SES’s provision of a core network of command, control and data gateways will be augmented with a number of customer satellite ground stations; satellite ground stations provisioned according to our customer needs, with regards to location, size and infrastructure requirements. We expect a number of these customer satellite ground stations to include virtualised installations of the cloud at the edge of the deployed networks, thus improving the end-user experience.”

Follow us on:

Read our Blogs >

Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 361 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye